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Abstract
The requirement that an invention have utility is one of the most fundamental of the patent laws. In the United
States, for example, the concept of utility is rooted in the Constitution: Article 1, Section 8, gives Congress the
power to grant exclusive rights to inventors in order “[t]o promote the progress of Science and useful Arts.”
Other jurisdictions recognize utility in the form of inventions that have “industrial applicability” or are
“capable of exploitation in industry,” with all of these terms and phrases generally viewed as being
synonymous.
Historically, nearly every jurisdiction has excluded some type of invention from patentability as lacking utility.
A common and enduring utility-based exclusion is the perpetual motion machine, with the justification being
scientific: because perpetual motion is not physically possible, an invention which claims such a feature
cannot in fact work and therefore fundamentally lacks utility. Jurisdictions also make exclusions on policy
grounds. In Europe, for example, methods of treating human and animal bodies are not patentable, but the
justification for doing so, which previously was based on lack of industrial applicability, is now expressly linked
to public health policy. In an ever-more global economy, inventions are at the heart of commercial transactions
that know no geographic boundaries and are increasingly valued for their job and wealth creation. Obtaining
patent protection in multiple jurisdictions therefore is increasingly common. At least to reduce costs and
increase efficiency, patent owners, policymakers and practitioners alike have sought increased inter
jurisdictional cooperation and patent law harmonization in the patent examination and granting process.
Recent publications, however, have identified a developing trend in Canada in which Canadian courts and the
Canadian Intellectual Property Office are interpreting and applying the historically well-settled and generally
harmonized utility requirement in a new and different way, in particular with respect to patents for
pharmaceutical products. As a result, applicants for Canadian patents must meet conditions and overcome
hurdles not required by other major patent offices.
This article will compare Canada’s implementation and treatment of the utility requirement with the
implementation and treatment practiced in the United States and Europe—two jurisdictions that represent
prevailing approaches to utility and also constitute a major share of the world’s patenting activity. The article
will first examine the statutory and judicial situation in each of the jurisdictions, including a review of the
major international treaties and agreements to which each is subject. It will then present a case study that
looks at the judicial challenges brought against various members of a single patent family in the United States,
Europe, and Canada, and compare the results of those challenges. This analysis, we believe, reveals that the
recent shift in Canada’s approach to the utility requirement conflicts with international norms and thus
presents implications for patentees, patent law harmonization, and international treaty obligations.
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I. INTRODUCTION 
The requirement that an invention have utility is one of the most fundamental 
of the patent laws.  In the United States, for example, the concept of utility is 
rooted in the Constitution: Article 1, Section 8, gives Congress the power to grant 
exclusive rights to inventors in order “[t]o promote the progress of Science and 
useful Arts.”
1
  Other jurisdictions recognize utility in the form of inventions that 
have “industrial applicability”
2
 or are “capable of exploitation in industry,”
3
 with 
all of these terms and phrases generally viewed as being synonymous.
4
   
Historically, nearly every jurisdiction has excluded some type of invention 
from patentability as lacking utility.
5
  A common and enduring utility-based 
exclusion is the perpetual motion machine, with the justification being scientific: 
because perpetual motion is not physically possible, an invention which claims 
such a feature cannot in fact work and therefore fundamentally lacks utility.
6
  
Jurisdictions also make exclusions on policy grounds.  In Europe, for example, 
methods of treating human and animal bodies are not patentable, but the 
justification for doing so, which previously was based on lack of industrial 
applicability,
7
 is now expressly linked to public health policy.
8
 
                                                                                                                                     
1
 U.S. CONST. art. I, § 8, cl. 8 (emphasis added). 
2
 See WORLD INTELLECTUAL PROP. ORG., PATENT COOPERATION TREATY INTERNATIONAL 
SEARCH AND PRELIMINARY EXAMINATION GUIDELINES,  § A14.01[1] (Oct. 3, 2011) [hereinafter 
PCT GUIDELINES], available at http://www.wipo.int/pct/en/texts/pdf/ispe.pdf. 
3
 See EUROPEAN PATENT OFFICE, GUIDELINES FOR EXAMINATION IN THE EUROPEAN PATENT 
OFFICE, pt. C, ch. II, § 4.12 (Apr. 2010) [hereinafter EPO EXAMINATION GUIDELINES] (referring to 




 See PCT GUIDELINES, supra note 2. 
5
 See Juicy Whip, Inc. v. Orange Bang, Inc., 185 F.3d 1364, 1367–68 (Fed. Cir. 1999) 
(“[Y]ears ago courts invalidated patents on gambling devices on the ground that they were 
immoral, but that is no longer the law . . . . ‘Congress never intended that the patent laws should 
displace the police powers of the States, meaning by that term those powers by which the health, 
good order, peace and general welfare of the community are promoted.’ . . . [W]e find no basis in 
section 101 to hold that inventions can be ruled unpatentable for lack of utility simply because 
they have the capacity to fool some members of the public.”) (citations omitted); see also U.S. 
PATENT & TRADEMARK OFFICE, U.S. DEP’T COMMERCE, MPEP § 706.03(II) (8th  ed. Rev. 8, July 
2010) [hereinafter MPEP]. 
6
 See MPEP, supra note 5, § 706.03(II) (“A rejection on the ground of lack of utility includes 
the more specific grounds of inoperativeness, involving perpetual motion.”); EPO EXAMINATION 
GUIDELINES, supra note 3, pt. C, ch. II, § 4.11 (“[S]uccessful performance of the invention is 
inherently impossible because it would be contrary to well-established physical laws – this applies 
e.g. to a perpetual motion machine.”). 
7
 European Patent Convention art. 52(4), Oct. 5, 1973, 1065 U.N.T.S. 199 (1973) [hereinafter 
EPC-1973], available at http://www.epo.org/law-practice/legal-texts/html/epc/1973/e/ar52.html 
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In an ever-more global economy, inventions are at the heart of commercial 
transactions that know no geographic boundaries and are increasingly valued for 
their job and wealth creation.  Obtaining patent protection in multiple jurisdictions 
therefore is increasingly common.
9
  At least to reduce costs and increase 
efficiency,
10
 patent owners, policymakers and practitioners alike have sought 
increased interjurisdictional cooperation and patent law harmonization in the 
patent examination and granting process.
11
  Recent publications, however, have 
                                                                                                                                     
 
(“Methods for the treatment of the human or animal body by surgery or therapy and diagnostic 
methods practised on the human or animal body shall not be regarded as inventions which are 
susceptible of industrial application within the meaning of [Article 52(1)].” (emphasis added)). 
8
 European Patent Convention art. 53(c), Oct. 5, 1973, 1065 U.N.T.S. 199 (as amended Nov. 
29, 2000) [hereinafter EPC-2000], available at 
http://documents.epo.org/projects/babylon/eponet.nsf/0/7bacb229e032863dc12577ec004ada98/$F
ILE/EPC_14th_edition.pdf; Shamnad Basheer et al., Patent Exclusions that Promote Public 
Health Objectives, in AN EXPERT’S STUDY ON EXCLUSIONS FROM PATENTABLE SUBJECT MATTER 
AND EXCEPTIONS AND LIMITATIONS TO THE RIGHTS Annex IV (2010) available at 
http://www.wipo.int/edocs/mdocs/scp/en/scp_15/scp_15_3-annex4.pdf (last visited Feb. 16, 2012) 
(“The European Patent Convention (EPC) categorically excludes ‘methods of medical and 
veterinary treatment’ from patentability.  Such inventions are excluded to ensure that people who 
carry out medical or veterinary treatments are not inhibited by patents.”). 
9
 World Intellectual Prop. Org. [WIPO], World Intellectual Property Indicators (2011), 
available at 
http://www.wipo.int/export/sites/www/freepublications/en/intproperty/941/wipo_pub_941_2011.p
df.  “The trend in total patent families was stable until 1994 and has followed an upward trend 
since then . . . . Meanwhile, the number of foreign-oriented patent families more than doubled – 
from 107,318 in 1985 to 257,321 in 2008 – reflecting the increasing tendency for applicants to file 
abroad.”  Id. at 56–57.  The United States leads all others in foreign-oriented patent family filings 
(i.e., families for which the first-filed application in a family is foreign) with 22.3% of all foreign-
oriented families including a filing at the U.S. Patent & Trademark Office (USPTO), followed by 
the European Patent Office (EPO) (19.3%), China (52.2%) and Canada (46.9%).  Id. at 59.  With 
respect to residents, 49.4% of all applications filed in the USPTO in 2010 were filed by U.S. 
residents, which is similar to the EPO’s 49.3%; in Canada, only 12.8% of applications were filed 
by Canadian residents in 2010.  Id. at 43. 
10
 JAKKRIT KUANPOTH, PATENT RIGHTS IN PHARMACEUTICALS IN DEVELOPING COUNTRIES: 
MAJOR CHALLENGES FOR THE FUTURE 12 (Edward Elgar Publ’g. Ltd. 2010) (“[A]ttempts have 
been made to establish regional co-operation regarding patent administration in order to increase 
efficiency and reduce costs of granting and maintaining patents.  In recent years, there has been a 
drive from certain countries towards the increased harmonization of patent law standards as well 
as patent granting procedures.”). 
11
 See, e.g., David Kappos,Under Sec’y for Commerce for Intellectual Prop. & Dir. of the U.S. 
Patent & Trademark Office, Remarks as prepared for delivery at the WIPO Symposium – 
Promoting Innovation & Creativity: The America Invents Act and a Global Call for 
Harmonization, (Sept. 22, 2011) (transcript available at 
http://www.uspto.gov/news/speeches/2011/kappos_wipo.jsp)  (“I’ll make the case for the urgency 
of harmonization, a mandate to better manage the collective challenges our global IP system faces 
in a 21
st
 century economy.  The public must have confidence that the patent system is striking the 
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identified a developing trend in Canada in which Canadian courts and the 
Canadian Intellectual Property Office are interpreting and applying the 
historically well-settled and generally harmonized utility requirement in a new 
and different way, in particular with respect to patents for pharmaceutical 
products.
12
  As a result, applicants for Canadian patents must meet conditions and 
overcome hurdles not required by other major patent offices.   
This article will compare Canada’s implementation and treatment of the utility 
requirement with the implementation and treatment practiced in the United States 
and Europe—two jurisdictions that represent prevailing approaches to utility and 
also constitute a major share of the world’s patenting activity.  The article will 
first examine the statutory and judicial situation in each of the jurisdictions, 
including a review of the major international treaties and agreements to which 
each is subject.  It will then present a case study that looks at the judicial 
challenges brought against various members of a single patent family in the 
United States, Europe, and Canada, and compare the results of those challenges.  
This analysis, we believe, reveals that the recent shift in Canada’s approach to the 
utility requirement conflicts with international norms and thus presents 
implications for patentees, patent law harmonization, and international treaty 
obligations. 
                                                                                                                                     
 
right balance between incentives to innovate and access to those new innovations.  Through global 
synergy and collaboration, we have a unique opportunity, right away, to meet these challenges – 
and I believe it is imperative we do that, and act by moving towards a more standardized global 
patent system.”); Dongwook Chun, Patent Law Harmonization in the Age of Globalization: The 
Necessity and Strategy for  Pragmatic Outcome, 93 J. PAT. & TRADEMARK OFF. SOC’Y 127, 138 
(2011) (“The majority of the international patent community is and has been supportive of the idea 
of uniformity, recognizing the value of creating a uniform patent law on a global scale.”); Dennis 
Crouch, Some Hope for the Patent Reforms, PATENTLY-O (Sept. 7, 2011), 
http://www.patentlyo.com/patent/2011/09/by-dennis-crouch-at-this-point-it-appears-very-likely-
that-the-leahy-smith-america-invents-act-hr-1249-will-become-law-a.html (“Many patent 
applications are independently and redundantly examined in patent offices around the world.  That 
scenario appears ripe for some level of cooperation and coordination that could seemingly reduce 
delay and costs while improving quality.”). 
12
 See, e.g., Charles E. Lipsey &  L. Scott Burwell, Useful in the United States, But Not in 
Canada: Divergent Applications of the Statutory Utility Requirements, BLOOMBERG LAW 
REPORTS, Oct. 3, 2011, available at 
http://www.finnegan.com/resources/articles/articlesdetail.aspx?news=59ab301b-1d14-441d-85db-
67b67f9243ed; Arvie Anderson & Lawrence Welch, The Canadian Patent Promise: A Concern 
for Pharmaceutical Innovators?, IPO COMMITTEE NEWSL. (Intellectual Prop, Owner’s Assoc., 
Washington, D.C.), Dec. 2011, available at 
http://www.morganlewis.com/pubs/IP_IPOIsolatedDNASequences_dec2011.pdf.  This selective 
application is significant because, in 2009 alone, 62,122 pharmaceutical patent applications were 
filed worldwide; from 2005 to 2009, 5,584 were filed in Canada.  World Intellectual Property 
Indicators, supra note 9, at 76–77. 
[3:1 2012] Usefulness Varies by Country:             5 
The Utility Requirement of Patent Law  




II. AN OVERVIEW OF UTILITY IN THE UNITED STATES, EUROPE & CANADA 
Utility requirements for patent applications are one of the most basic and 
fundamental.  In general, a common theme exists across jurisdictions about what 
might be “useful.”
13
  It is agreed that some level of utility (or “industrial 
applicability,” as it is known in Europe
14
) must be shown, but the question is how 
much or to what degree.  Following the 2002 decision by the Supreme Court of 
Canada in Apotex Inc. v. Wellcome Foundation Ltd.,
15
 as expanded by the 
Canadian Court of Appeal in Eli Lilly Canada Inc. v. Apotex Inc.,
16
 Canada began 
requiring that patent applicants do more to prove utility prior to filing than is 
required by other jurisdictions and international agreements.  To begin to put this 
assertion into context, this section discusses the respective statutory laws, patent 
office administrative rules, and jurisprudence of the United States, Europe, and 
Canada.  
A. United States 
In the United States, § 101 of the Patent Act defines what is patentable: 
“Whoever invents or discovers any new and useful process, machine, 
manufacture, or composition of matter, or any new and useful improvement 
thereof may obtain a patent therefor, subject to the conditions and requirements of 
this title.”
17
  To satisfy § 101, an applicant must claim an invention that falls 




The Manual of Patent Examination Procedure (MPEP) administered by the 
United States Patent & Trademark Office (USPTO) provides examination 
                                                                                                                                     
13
 See, e.g., Brenner v. Manson, 383 U.S. 519, 536 (1966) (“But a patent is not a hunting 
license.  It is not a reward for the search, but compensation for its successful conclusion. ‘[A] 
patent system must be related to the world of commerce . . . .’” (quoting Application of Ruschig, 
343 F.2d 965, 970 (C.C.P.A. 1965)); PCT GUIDELINES, supra note 2. 
14
 See infra Part II.B. 
15
 [2002] 4 S.C.R. 153 (Can.). 
16
 [2009] F.C.A. 97, para. 18 (Can.) (The Court expressly required that a patent specification 
must include “a disclosure such that a person skilled in the art, given that disclosure, could have as 
the inventors did, soundly predicted that the invention would work once reduced to practice.” 
(emphasis added)). 
17
 35 U.S.C. § 101 (2006) (emphasis added); see also MPEP, supra note 5, § 2107.01.  Section 
101 was not amended by the recent America Invents Act.  See Leahy-Smith America Invents Act 
of 2011, Pub. L. No. 112-29, 125 Stat. 284. 
18
 MPEP, supra note 5, § 2107.01 (“As interpreted by the Federal courts, 35 U.S.C. 101 has 
two purposes.  First, 35 U.S.C. 101 defines which categories of inventions are eligible for patent 
protection.  An invention that is not a machine, an article of manufacture, a composition or a 
process cannot be patented.  Second, 35 U.S.C. § 101 serves to ensure that patents are granted on 
only those inventions that are ‘useful.’” (citations omitted)). 
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guidelines for the utility requirement of § 101.
19
  To demonstrate that an invention 
is useful, an applicant must show that the invention has “specific and substantial 
utility” or discloses sufficient information about the invention such that its utility 
is immediately apparent to those familiar with the technological field, so-called 
“well-established utility.”
20
   
Specific utility must be specific to the subject matter of the claimed invention 
and not merely generally applicable to the “broad class of the invention.”
21
  For 
example, a statement that an invention is useful to diagnose disease without 
disclosing a particular disease or condition would lack specific utility, whereas 
one that discloses a biological activity and “reasonably correlates that activity to a 
disease condition” would establish sufficient specific utility.
22
   
Substantial utility can be equated to showing a “real world” use.
23
  To 
establish substantial utility, an applicant must show that an invention is useful as 
disclosed in its current form, rather than at some time in the future pending 
additional research.
24
  “Utilities that require or constitute carrying out further 
research to identify or reasonably confirm a ‘real world’ context of use are not 
substantial utilities.”
25
  The MPEP is careful to qualify, however, that “in its 
                                                                                                                                     
19
 Id. § 2107.01.  The MPEP further provides that inventions in various different technological 
fields are each subject to the same legal requirements with respect to utility, there being “no basis 
in the statutes or decisions for requiring any more conclusive evidence of operativeness in one 
type of case than another.”  Id. § 2107.01(III) (citing In re Chilkowsky, 229 F.2d 457, 461–62 
(C.C.P.A. 1956)).  “Courts have repeatedly found that the mere identification of a pharmacological 
activity of a compound that is relevant to an asserted pharmacological use provides an ‘immediate 
benefit to the public’ and thus satisfies the utility requirement.”  MPEP, supra note 6, § 
2107.01(III).  
20
 MPEP, supra note 5, § 2107.01 (citing Brenner v. Manson, 383 U.S. 519, 148 U.S.P.Q. 689 
(1966); In re Fisher, 421 F.3d 1365, 76 U.S.P.Q.2d 1225 (Fed. Cir. 2005); In re Ziegler, 992 F.2d 
1197, 26 U.S.P.Q.2d 1600 (Fed. Cir. 1993)).  See also MPEP, supra note 5, § 2107.02(II) (“An 
invention has a well-established utility if (i) a person of ordinary skill in the art would 
immediately appreciate why the invention is useful based on the characteristics of the invention 
(e.g., properties or applications of a product or process), and (ii) the utility is specific, substantial, 
and credible.”). 
21
 MPEP, supra note 5, § 2107.01(I)(A).  Many of the examples of specific vs. general utility 
provided in the MPEP are related to pharmacological and biotech inventions.  “[I]ndicating that a 
compound may be useful in treating unspecified disorders, or that the compound has ‘useful 
biological’ properties, would not be sufficient to define a specific utility for the compound.”  Id.   
22
 Id.  “Assertions that fall in the former category are insufficient to define a specific utility for 
the invention, especially if the assertion takes the form of a general statement that makes it clear 
that a ‘useful’ invention may arise from what has been disclosed by the applicant.”  Id. 
23
 MPEP, supra note 5, § 2107.01(I)(B). 
24
 Id. (citing In re Fisher, 421 F.3d at 1371). 
25
 MPEP, supra note 5, § 2107.01(I)(B) (“For example, both a therapeutic method of treating a 
known or newly discovered disease and an assay method for identifying compounds that 
themselves have a ‘substantial utility’ define a ‘real world’ context of use.  An assay that measures 
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current form” is not intended to mean that a claimed invention must be “currently 
available,” but rather that any reasonable use that is identified by the applicant 




A deficiency under § 101 generally leads to a deficiency under § 112 , the first 
paragraph of which provides that the specification of a patent application:  
[S]hall contain a written description of the invention, and of the 
manner and process of making and using it, in such full, clear, 
concise, and exact terms as to enable any person skilled in the art 
to which it pertains, or with which it is most nearly connected, to 
make and use the same, and shall set forth the best mode 
contemplated by the inventor of carrying out his invention.
27
 
Section 112 therefore has been interpreted to set forth three separate 
requirements: written description, enablement, and best mode.
28
  The 
interrelationship between §§ 101 and 112 stems from the reasoning that if an 
invention lacks utility, an application for that invention cannot enable one to use 
it.
29




                                                                                                                                     
 
the presence of a material which has a stated correlation to a predisposition to the onset of a 
particular disease condition would also define a ‘real world’ context of use in identifying potential 
candidates for preventive measures or further monitoring.  On the other hand, the following are 
examples of situations that require or constitute carrying out further research to identify or 
reasonably confirm a ‘real world’ context of use and, therefore, do not define ‘substantial utilities’: 
(A) Basic research such as studying the properties of the claimed product itself or the mechanisms 
in which the material is involved; (B) A method of treating an unspecified disease or condition; 
(C) A method of assaying for or identifying a material that itself has no specific and/or substantial 
utility; (D) A method of making a material that itself has no specific, substantial, and credible 
utility; and (E) A claim to an intermediate product for use in making a final product that has no 




 35 U.S.C. § 112 (2006). 
28
 See, e.g., University of Rochester v. G.D. Searle & Co., 358 F.3d 916, 921 (Fed. Cir. 2004).  
Best mode will be affected by the recently enacted America Invents Act in that it will no longer be 
available as an invalidity defense in litigation, but the requirement of § 112 will remain as a 
requirement of patentability.  Leahy-Smith America Invents Act of 2011, supra note 17, § 15. 
29
 See In re Ziegler, 992 F.2d 1197, 1200–01 (Fed. Cir. 1993); see also MPEP, supra note 5, § 
2107.01(IV). 
30
 MPEP, supra note 5, § 2107.01(IV) (“The fact that an applicant has disclosed a specific 
utility for an invention and provided a credible basis supporting that specific utility does not 
provide a basis for concluding that the claims comply with all the requirements of 35 U.S.C. 112, 
first paragraph. For example, if an applicant has claimed a process of treating a certain disease 
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An asserted utility, that is, a statement in the patent application that the 
claimed invention is useful for some purpose, creates a presumption of utility.
31
  
If the asserted utility is “credible,” rejection for lack of utility is inappropriate.
32
  
Examiners will treat an assertion as credible unless: (1) the logic underlying the 
assertion is seriously flawed; or (2) the facts upon which the assertion is based are 
inconsistent with the logic underlying the assertion.
33
  The standard for 
overcoming the presumption of utility is that it is more likely than not that one of 
ordinary skill in the art would doubt or question the truth of the statement of 
utility.
34
  In some situations, an examiner may request additional information 
from an applicant to support an asserted utility, for example, if an asserted utility 
is one that would seem unlikely to one of ordinary skill in the art.
35
  Such 
requests, however, should be imposed “rarely, and only if necessary to support the 
scientific credibility of the asserted utility.”
36
 
Fundamentally, the MPEP states that “[t]here is no predetermined amount or 
character of evidence that must be provided by an applicant to support an asserted 
utility, therapeutic or otherwise.  Rather, the character and amount of evidence 
needed to support an asserted utility will vary depending on what is claimed.”
37
  
The MPEP specifically addresses “special considerations” related to therapeutic 
and pharmacologic utilities, providing that in those areas, too, “all that is required 
                                                                                                                                     
 
condition with a certain compound and provided a credible basis for asserting that the compound 
is useful in that regard, but to actually practice the invention as claimed a person skilled in the 
relevant art would have to engage in an undue amount of experimentation, the claim may be 
defective under 35 U.S.C. 112, but not 35 U.S.C. 101.”)  
31
 See, e.g., In re Langer, 503 F.2d 1380, 1391 (C.C.P.A. 1974); see also MPEP, supra note 5, 
§ 2107.02(III)(A).  The asserted utility, however, must be commensurate in scope with the claimed 




 MPEP, supra note 5, § 2107.02(III)(B).  Note that “[s]pecial care should be taken when 
assessing the credibility of an asserted therapeutic utility for a claimed invention. In such cases, a 
previous lack of success in treating a disease or condition, or the absence of a proven animal 
model for testing the effectiveness of drugs for treating a disorder in humans, should not, standing 
alone, serve as a basis for challenging the asserted utility under 35 U.S.C. 101.” Id. 
34
 See In re Langer, 503 F.2d at 1391; see also MPEP, supra note 5, § 2107.02(III)(A).  U.S. 
courts generally are reluctant to uphold § 101 rejections “solely on the basis that the applicant’s 
opinion as to the nature of the specific and substantial utility was inaccurate.”  Id. § 2107.01(I); 
see also Nelson v. Bowler, 626 F.2d 853, 856 (C.C.P.A. 1980) (finding that proof of any 
pharmacological activity of a drug was sufficient to find “practical utility”). 
35




 MPEP, supra note 6, § 2107.02(VII). 
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is a reasonable correlation between the activity and the asserted use.”
38
  
Furthermore, courts in the United States generally are not receptive to rejections 
under § 101 for lack of utility, with the MPEP noting that it is “striking” that § 
101 rejections were almost always overturned where a reasonable evidentiary 
showing supporting an asserted therapeutic utility was made by the applicant.
39
  
The MPEP also reminds examiners that, with respect to therapeutic and 
pharmacologic inventions, the role of the USPTO is to examine patent 
applications with respect to the patent laws, not determine whether, e.g., a drug is 
safe for sale, use or distribution.
40
 
In re Fisher, a 2005 decision of the United States Court of Appeals for the 
Federal Circuit, illustrates the approach to the utility requirement adopted in the 
United States.
41
  In Fisher, the patentee sought to patent certain “expressed 
sequence tags,” or “ESTs,” but was rejected for failing to express a specific utility 
for the ESTs, as the disclosed genes for which the ESTs corresponded had no 
                                                                                                                                     
38
 MPEP, supra note 5, § 2107.03(I) (“An applicant can establish this reasonable correlation by 
relying on statistically relevant data documenting the activity of a compound or composition, 
arguments or reasoning, documentary evidence (e.g., articles in scientific journals), or any 
combination thereof. The applicant does not have to prove that a correlation exists between a 
particular activity and an asserted therapeutic use of a compound as a matter of statistical 
certainty, nor does he or she have to provide actual evidence of success in treating humans where 
such a utility is asserted.” (citing Nelson v. Bowler, 626 F.2d 853, 857 (C.C.P.A. 1980)).  
39
 MPEP, supra note 5, § 2107.03(III).  “In no case has a Federal court required an applicant to 
support an asserted utility with data from human clinical trials.”  Id.  Regarding human clinical 
trials, the USPTO:  
[S]hould not impose on applicants the unnecessary burden of providing evidence 
from human clinical trials. There is no decisional law that requires an applicant 
to provide data from human clinical trials to establish utility for an invention 
related to treatment of human disorders . . . . Before a drug can enter human 
clinical trials, the sponsor, often the applicant, must provide a convincing 
rationale to those especially skilled in the art (e.g., the Food and Drug 
Administration) that the investigation may be successful. Such a rationale would 
provide a basis for the sponsor’s expectation that the investigation may be 
successful. In order to determine a protocol for phase I testing, the first phase of 
clinical investigation, some credible rationale of how the drug might be effective 
or could be effective would be necessary.  Thus, as a general rule, if an 
applicant has initiated human clinical trials for a therapeutic product or 
process, Office personnel should presume that the applicant has established that 
the subject matter of that trial is reasonably predictive of having the asserted 
therapeutic utility.  
 
MPEP, supra note 5, § 2107.03(IV). 
40
 Id. § 2107.03(V). 
41
 In re Fisher, 421 F.3d 1365 (Fed. Cir. 2005). 
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known function at the time.
42
  On appeal, Fisher asserted that the Board of Patent 
Appeals and Interferences (BPAI) incorrectly applied a heightened utility 
standard.
43
  The Federal Circuit rejected the argument holding that the proposed 
utility failed to meet the ordinary utility standard.
44
  The court reasoned that a 
claimed invention whose only stated utility was use with genes that have no 
known use cannot be reasonably found to meet the utility standard.
45
  Fisher 
exemplifies the United States approach to the utility requirement, namely that the 
requirement is met so long as the specified utility is reasonable and not an attempt 




 uses a different term to describe the standard, its approach 
to the utility requirement is remarkably similar to that of the United States.  The 
European Patent Convention (EPC) establishes that inventions which are new, 
involve an inventive step, and are susceptible of industrial application are 
patentable.
47
  Being “susceptible of industrial application” is Europe’s form of 
“utility,” and an invention is susceptible of industrial application if “it can be 
made or used in any kind of industry.”
48
  Rule 42 of the Implementing 
Regulations of the EPC deals with the content of the description that must be 
provided in a European patent application and states that the description shall 
“indicate explicitly, when it is not obvious from the description or nature of the 
invention, the way in which the invention is industrially applicable.”
49
   
                                                                                                                                     
42
 Id. at 1368–69. 
43
 Id. at 1369–70. 
44
 Id. at 1374. 
45
 Id.  
46
 Here “Europe” refers to the European Patent Organisation, an intergovernmental 
organization established in 1977 on the basis of the European Patent Convention.  See infra notes 
47–61 and accompanying text.  The European Patent Organisation has two bodies, the European 
Patent Office (EPO) and the Administrative Council.  The Administrative Council of the European 
Patent Organisation, EUROPEAN PAT. OFF., http://www.epo.org/about-
us/organisation/administrative-council.html (last updated  Feb. 2, 2011).  See infra note 61 and 
accompanying text for a discussion regarding the national laws of the European countries. 
47
 EPC-2000, supra note 8, art. 52.  Discoveries, scientific theories and mathematical methods; 
aesthetic creations; schemes, rules and methods for performing mental acts, playing games or 
doing business, and programs for computers; and presentations of information are all specifically 
excluded from patentability.  Id. 
48
 Id. art. 57.  “Industry” generally is understood to mean “in its broadest sense.”  See EPO 
EXAMINATION GUIDELINES, supra note 3, pt. C, ch. IV, § 5.1; WIPO, STANDING COMMITTEE ON 
THE LAW OF PATENTS, “Industrial Applicability” and “Utility” Requirements: Commonalities and 
Differences, SCP/9/5 ¶¶ 4, 12 (Mar. 17, 2003), available at 
http://www.wipo.int/edocs/mdocs/scp/en/scp_9/scp_9_5.pdf. 
49
 EPC-2000, supra note 8, at R. 42(1)(f). 
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Examiners follow the Guidelines for Examination in the European Patent 
Office (EPO Examination Guidelines) to examine patent applications.
50
  The EPO 
Examination Guidelines begin by defining, in accordance with the EPC, that there 
are four basic requirements for patentability in Europe: (1) there must be an 
invention, belonging to any field of technology; (2) the invention must be 
susceptible of industrial application; (3) the invention must be new; and (4) the 
invention must involve an inventive step.
51
   
With respect to industrial application, the EPO Examination Guidelines state 
that “[t]he description should indicate explicitly the way in which the invention is 
capable of exploitation in industry.”
52
  The EPC hypothesizes that:  
[I]n most cases, the way in which the invention can be exploited in 
industry will be self-evident, so that no more explicit description 
on this point will be required; but there may be a few instances, 
e.g., in relation to methods of testing, where the manner of 
industrial exploitation is not apparent and must therefore be 
explicitly indicated.
53
   
In one case, the EPO Technical Board of Appeal considered an appeal of a refusal 
of claims as being not susceptible of industrial application under EPC Article 
57.
54
  Claim 1 of the application at issue was directed to a method of improving 
the bodily appearance of a non-opiate-addicted mammal by orally administering 
naltrexone or a pharmaceutically effective salt thereof in order to reduce appetite, 
and repeating the dosage until a “cosmetically” beneficial loss of body weight 
occurred.
55
  The specific ground for refusing the claims was that the subject 




In its appeal, Appellant E.I. Du Pont De Nemours & Co. argued that “the 
claims need not necessarily be restricted to industrial application” and that “[t]he 
                                                                                                                                     
50
 See EPO EXAMINATION GUIDELINES, supra note 3. 
51
 Id. pt. C, ch. IV, § 1.1.  Also, with respect to gene sequences specifically, “The invention 
claimed must have such a sound and concrete technical basis that the skilled person can recognise 
that its contribution to the art could lead to practical exploitation in industry.”  Id. § 5.4. 
52




 Case T-144/83, E.I. du Pont de Nemours & Co., 1986 O.J. E.P.O. 301, available at 
http://archive.epo.org/epo/pubs/oj1986/p295_336.pdf. 
55
 Id. at 302. 
56
 Id. (“The treatment of a human being with such a drug was essentially biological in nature 
and therefore the administration of the same could not be regarded as susceptible to industrial 
application.”). 
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word ‘industry’ should be given a broad interpretation . . . .”
57
  The Board of 
Appeals agreed, finding the subject matter of the claims was patentable under 
former EPC Article 52(4).
58
 
According to the provision of [EPC Article 52(4)] methods for 
treatment of the human or animal body by therapy shall not be 
regarded as susceptible to industrial application.  Such exclusions 
from patentability must be construed narrowly and should not 
apply to treatments which are not therapeutic in character . . . . 
[Claim 1] clearly covers a method of cosmetic use and is unrelated 
to the therapy of human or animal body in the ordinary sense.
59
 
The invention was also found to comply with EPC Article 57 (Industrial 
Application) because the invention “can be used by enterprises whose object is to 
beautify the human or animal body,” and such enterprises in the cosmetic field are 
part of industry since “‘industry’ implies that an activity is carried out 
continuously, independently and for financial gain.”
60
 
Thus, while the terminology varies (“utility” in the United States but 
“susceptible of industrial application” in Europe), the approaches of the 
jurisdictions are very similar with respect to the level of disclosure required and 
the deference given to asserted utility.  The same approach has been adopted by 
the individual countries of Europe, the national laws of which tend to reflect the 
EPC and therefore will not be discussed individually herein.
61
 
                                                                                                                                     
57
 Id. at 303. 
58
 Id. at 304; Act Revising the Convention on the Grant of European Patents, June 28, 2001, 
2007 O.J. E.P.O. SPEC. ED. 1 (repealing Article 52(4), but a provision containing the same 
wording was added in Article 53(c)), available at  
http://archive.epo.org/epo/pubs/oj007/01_07/special_edition_1_epc_2000.pdf. 
59
 E.I. du Pont de Nemours & Co., 1986 O.J. E.P.O. at 304 (“The fact that a chemical product 
has both a cosmetic and therapeutic effect when used to treat the human or animal body does not 
render the cosmetic treatment unpatentable.”). 
60
 Id. at 305. 
61
 See, e.g., Patents Act, 1977, c. 37 § 4 (U.K.) (“[A]n invention shall be taken to be capable of 
industrial application if it can be made or used in any kind of industry, including agriculture.”), 
available at http://www.legislation.gov.uk/ukpga/1977/37/pdfs/ukpga_19770037_en.pdf; UNITED 
KINGDOM INTELLECTUAL PROP. OFFICE, EXAMINATION GUIDELINES § 4(1) (July 2011), available 
at http://www.ipo.gov.uk/practice-sec-004.pdf; Basheer et al., supra note 8, at n.82 
(“Illustratively, Section 4A of the 1977 Act in the UK mirrors Article 53(c) of the EPC.”); see also 
Press Summary, Supreme Court of the U.K., Human Genome Sciences Inc. (Appellant) v. Eli Lilly 
and Company Limited (Respondent) [2011] UKSC 51, (Nov. 2, 2011) available at 
http://www.eplawpatentblog.com/2011/November/2011.11.02%20HGS%20v%20Eli%20Lilly%2
0-%20Press%20Summary.pdf (“There is very little UK authority on the topic of industrial 
applicability, particularly as regards biological material and the applicable principles are really to 
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The Canadian requirement of utility differs from that of the rest of the world 
by making it effectively impossible to maintain patents in which no actual 
working embodiments existed as of the filing date.  The reason for this distinction 
is the doctrine of sound prediction.  Understanding the Canadian requirement 
therefore requires an understanding of the role that the doctrine of sound 
prediction plays in it. 
In Canada, an invention is “any new and useful art, process, machine, 
manufacture or composition of matter, or any new and useful improvement in any 
art, process, machine, manufacture or composition of matter.”
62
  In light of this 
statutory basis, the Canadian Intellectual Property Office (CIPO) provides in its 
Manual of Patent Office Practice (MOPOP) that utility “is an essential aspect of 
an invention” and “can be considered as a requirement for an invention to be 
operable, controllable and reproducible.”
63
  Thus, an invention is operable if it 
works for its intended purpose.
64
 
                                                                                                                                     
 
be found in the jurisprudence of the EPO and the Board .  While the reasoning in each decision of 
the Board is not binding upon national courts, the courts should normally follow the jurisprudence 
of the EPO, particularly where the Board has adopted a consistent approach to an issue in a 
number of decisions as is the case with regard to the application of Article 57 to patents for 
biological material.” (citations omitted)).  On the issue of industrial applicability, the court in 
Human Genome Sciences allowed the appeal, finding that the lower court failed to follow the 
principles of the law by: 
[L]ooking for a description that showed a particular use for the product [that] 
had actually been demonstrated, rather than that the product had plausibly been 
shown to be usable for the purposes of research work which the Board must 
have taken to have regarded as an industrial activity in itself. 
   
Id. (citations omitted).   
62
 Canadian Patent Act, R.S.C. 1985, ch. P-4, § 2, available at http://laws-
lois.justice.gc.ca/PDF/P-4.pdf; CANADIAN INTELLECTUAL PROP. OFFICE, PATENT OFFICE, 
MANUAL OF PATENT OFFICE PRACTICE § 12.02 (1998 ed., rev. Dec. 2010) [hereinafter MOPOP], 
available at  http://www.ic.gc.ca/eic/site/cipointernet-internetopic.nsf/eng/h_wr00720.html. 
63
 MOPOP, supra note 62, § 12.08 (which also provides that “[t]he utility of [a particular] 
invention must be specific . . . practical . . . and credible.”). 
64
 Id. § 12.08.01 (“Where the utility of an invention is self-evident to the person skilled in the 
art, and no particular promise has been made in regard to any advantages of the invention (e.g. if 
the invention was to simplify a known invention), the self-evident utility is sufficient to meet the 
required standard.  Where, however, the inventors promise that their invention will provide 
particular advantages (e.g. will do something better or more efficiently or will be useful for a 
previously unrecognized purpose) it is this utility that the invention must in fact have.  Although 
an invention need only have one use in order to be patentable, where several uses are promised the 
applicant must be in a position to establish each of them.  For example, if a composition is 
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In its interpretation of the statute, the Supreme Court of Canada has held that 
utility does not exist if “the invention will not work, either in the sense that it will 
not operate at all or, more broadly, that it will not do what the specification 
promises that it will do”
65
 but that “[i]f when used in accordance with the 
directions contained in the specification the promised results are obtained, the 
invention is useful in the sense in which that term is used in patent law.”
66
  An 
invention also must be controllable and reproducible such that “the desired result 
must inevitably follow when the invention is put into practice.”
67
  Inventions that 




Utility must be established as of the time a patent is applied for and cannot be 
supported by evidence occurring after the filing date.
69
  To show utility, an 
applicant can: (1) disclose embodiments of the invention that actually work; or (2) 
disclose soundly predicted embodiments.
70
  The latter factor is referred to as the 
doctrine of sound prediction.  
The doctrine of sound prediction was invoked by the Canadian Supreme Court 
in Apotex Inc. v. Wellcome Foundation Ltd., which held that applicants must 
demonstrate that a claimed invention’s promised utility, or “promise of the 
                                                                                                                                     
 
promised to be useful as a drug, the applicant must be in a position to show that it is useful in the 
therapy of at least one disease.  If, however, it is promised to be useful as a drug for treating many 
diseases, the applicant must be in a position to establish its utility [see 12.08.03 & 12.08.05] in 
treating each of the diseases.”). 
65
 Consolboard, Inc. v. MacMillan Bloedel (Sask.), Ltd., [1981] 1 S.C.R. 504, 525 (Can.); see 
also MOPOP, supra note 62, § 12.08.01. 
66
 Consolboard, Inc. [1981] 1 S.C.R. 504, at 526; see also Unifloc Regents, Ld. v. Newstead 
Colliery, Ld. [1943] 60 R.P.C. 165, 184 (Can.). 
67
 MOPOP, supra note 62, § 12.08.02.  The MOPOP notes “that the idea that the ‘desired result 
must inevitably follow’ can refer to an accepted degree of success of a particular repetitive mass 




 Apotex, Inc. v. Wellcome Found. Ltd., [2002] 4 S.C.R. 153, para. 46 (Can.) (It is not enough 
for an applicant “to be able to buttress speculation with post-patent proof, and thereby to turn 
dross into gold.”); see also MOPOP, supra note 62, § 12.08.05.  If the application claims priority 
to an earlier application, the claims are only valid insofar as the priority document establishes the 
utility of invention described in the claims.  Id.; cf. In re Brana, 51 F.3d 1560 (Fed. Cir. 1995) 
(establishing utility by using a declaration prepared and submitted during the prosecution of the 
application showing a person of ordinary skilled in the art would not have doubted the asserted 
utility).  
70
 Apotex, [2002] 4 S.C.R. 153; see also MOPOP, supra note 62, § 12.08.03 (stating that 
disclosure of soundly predicted embodiments can be shown in applications “for which an 
appropriate basis exists upon which this utility can be predicted.”).   
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patent” as it is known in Canada,
71
 is “soundly predicted” as of the filing or 
priority date if no actual working embodiment exists.
72
  In doing so, the Supreme 
Court departed from the “patent friendly” origins of the doctrine of sound 
prediction that accepted the promise of the patent unless there was evidence of a 
lack of utility.
73
 The Supreme Court was seeking to prevent applicants from 
“buttress[ing] speculation with post-patent proof,” thereby allowing applicants to 
be rewarded for patenting what was effectively a guess.
74
  Although the 
Commissioner is required “by law” to reject a patent application where the 
invention is merely “arrived at by chance” and “cannot be reliably reproduced,”
75
 
the Court reasoned that the burden should be placed on the applicant to first 
establish utility before requiring the attacker to prove invalidity.
76
  Following 
Apotex, CIPO amended the MOPOP to incorporate the doctrine of sound 
prediction into the examination procedure.
77
 
Despite being referred to commonly as a “utility requirement,” the doctrine of 
sound prediction is unconcerned with whether the claimed invention can actually 
perform the promise of the patent.
78
  Instead, the doctrine looks solely at whether 
the applicant could have reasonably inferred that the claimed invention was 
suitable for the promise of the patent based on the evidence available at the filing 
or priority date.
79
  According to Apotex, the doctrine of sound prediction has three 
                                                                                                                                     
71
 Since “promise of the patent” is the accepted Canadian term for promised utility, we will use 
it here. 
72
 MOPOP, supra note 62, § 12.08.05.  If the application claims priority to an earlier 
application, the claims are only valid insofar as the priority document establishes the utility of 
invention described in the claims.  Id.  It is not enough for an applicant “to be able to buttress 
speculation with post-patent proof, and thereby to turn dross into gold.”  Id. (quoting Apotex, 
[2002] 4 S.C.R. 153, para. 46 (Binnie, J.). 
73
 See, e.g., Monsanto Co. v. Comm’r of Patents [1979] 2 S.C.R. 1108, 1121–22 (Can.) (“In my 
opinion the Commissioner cannot refuse a patent because the inventor has not fully tested and 
proved it in all its claimed applications. This is what he has done in this case by refusing to allow 
claims 9 and 16 unless restricted to what had been tested and proved before the application was 
filed. If the inventors have claimed more than what they have invented and included substances 
which are devoid of utility, their claims will be open to attack. But in order to succeed, such attack 
will have to be supported by evidence of lack of utility. At present there is no such evidence and 
there is no evidence that the prediction of utility for every compound named is not sound and 
reasonable.”). 
74
 Id. at 1127. 
75
 Apotex, [2002] 4 S.C.R. 153 (citing the Canadian Patent Act, supra note 62, § 40; see also 




 MOPOP, supra note 62, § 12.08.02.  The MOPOP notes “that the idea that the ‘desired result 
must inevitably follow’ can refer to an accepted degree of success of a particular repetitive mass 
production method,” and the accepted degree  of success can vary with particular arts.  Id. 
78
 Apotex, [2002] 4 S.C.R. 153. 
79
 Id. 
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prongs, requiring: (i) a factual basis, (ii) a line of sound reasoning based on the 
factual basis that leads to the desired result, and (iii) the provision of sufficient 
disclosure in the specification.
80
  
The factual basis prong can be established by examples of what could be 
found in “scientifically accepted laws or principles, in data forming part of the 
state of the art and which is referred to in the description, or in information 
forming part of the common general knowledge of the person skilled in the art.”
81
  
The factual basis must be established by evidence linked to a date that predates 
the filing date or earliest priority date.
82
 As such, according to Lilly, if an 
applicant neglects to include disclosure within the specification and cannot 
otherwise establish a factual basis preceding the filing date, any application in 
Canada claiming priority to an earlier priority application may be invalidated even 
if that earlier application arose in a jurisdiction that does not require the provision 
of a factual basis.
83
 
The general test for the sound reasoning prong of the doctrine of sound 
prediction is whether a person of ordinary skill in the art would accept the logic 
presented in the line of reasoning and derive from the prediction that the invention 
will provide the promise of the patent.
84
   
Although no inventor is required to understand why their invention 
works, this does not dilute the requirements for a sound prediction.  
If an inventor cannot articulate a line of reasoning to soundly 
connect their factual support (e.g. their examples) to the remaining 








 MOPOP, supra note 62, at § 12.08.04a. 
82
 G.D. Searle & Co. v. Novopharm Ltd. [2007] F.C. 81, para. 97 (Can.).  The United States 
and other jurisdictions do not have comparable requirements.  See supra note 69. 
83
 Eli Lilly Can. Inc. v. Apotex Inc., [2009] F.C.A. 97 (Can.). 
84
 Apotex, [2002] 4 S.C.R. 153; see also MOPOP, supra note 62, § 12.08.04b (“Since a sound 
line of reasoning is directed to a person skilled in the art, those elements of the sound line of 
reasoning that would be self-evident to the person skilled in the art in view of their common 
general knowledge do not need to be explicitly disclosed in the application . . . . It is not possible 
to provide exhaustive guidance on the types of reasoning which may be found to be ’sound.’  If 
brief, however, the soundness of a line of reasoning can be effectively assessed by asking whether 
the person skilled in the art (represented during examination by the examiner) would accept the 
logic presented in the line of reasoning and derive from the sound prediction as a whole an 
expectation that the invention will provide the promised utility.”).   
85
 MOPOP, supra note 62, § 12.08.04b; see also Monsanto Co. v. Comm’r of Patents, [1979] 2 
S.C.R. 1108 (Can.). 
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The result is that the court or a patent examiner must subjectively evaluate the 
scientific thought process of the applicant. 
For example, Canadian Patent No. 2, 225,626 was at issue in the post-Apotex 
case of Allergan, Inc. v. Minister of Health, and claimed a new use for a 
brimonidine compound as a topically applied neuro-protectant for the optic nerve 
and retina of humans from damage from glaucoma or ocular hypertension.
86
  In 
response to an action for infringement, the defendant asserted that the patent 
lacked utility since the tests disclosed in the specification upon which the patent 
applicant relied to illustrate utility were only in vivo tests in rats rather than 
topical testing in humans.
87
  To evaluate utility under the doctrine of sound 
prediction, the court was required to determine whether the results of the rat 
testing provided sufficient basis for a sound prediction that the claimed compound 
could provide the stated utility in treating humans.
88
  In other words, the court, as 
the legal fact-finder, must judge the scientific reasonableness of the applicant’s 
thought process regarding the chosen test procedure.
89
 
According to the Canadian Court of Appeal in Lilly, the disclosure prong of 
the Apotex sound doctrine analysis requires that “the patent must provide a 
disclosure such that a person skilled in the art, given that disclosure, could have as 
the inventors did, soundly predicted that the invention would work once reduced 
to practice.”
90
  The doctrine of sound prediction therefore places an additional 
                                                                                                                                     
86
 Allergan, Inc. v. Minister of Health [2011] F.C. 1316, para. 24 (Can.). 
87
 Id. para. 211.  Because the tests were not performed on humans, “the utility of that subject 
matter could not be soundly predicted as of the priority date . . . .”  Id. para. 193. 
88
 “The doctrine of sound prediction has three components, namely: [that] . . . the inventor 
must have had an articulable . . . and sound line of reasoning from which the desired result can be 
inferred from the factual basis . . . .”  Id. para. 216.  “Therefore, the key question that remains is 
whether the '626 Patent disclosed the factual basis on which a POSITA could soundly predict in 
June 1996 that the topical administration of brimonidine would have a neuroprotective effect in 
humans, once the invention was reduced to practice.”  Id. para. 220 (citing Merck & Co. v. Apotex 
Inc., [2010] F.C. 1265, para. 521 (Can.)). 
89
 Allergan, Inc. [2011] F.C. 1316, para. 220.  The Court ultimately found that the patent did 
not lack utility as: (1) the in vivo drug administration would have allowed the drug to navigate to 
the eye, (2) the included results demonstrated that the drug produced the proposed effect despite in 
vivo administration, and (3) expert testimony that the results would suggest to a POSITA that 
drugs would have a similar effect in humans.  Id. para. 223. 
90
 Eli Lilly Can. Inc. v. Apotex Inc., [2009] F.C.A. 97, para. 18 (Can.).  “The requirement for 
proper disclosure means that the person skilled in the art has to, through the specification [alone] . 
. . be provided with sufficient information to understand the basis of the sound prediction and to 
practice the entire scope of the claimed invention.”  MOPOP, supra note 62, § 17.03.02c (citing 
Eli Lilly Can. Inc. v. Apotex Inc. [2008] F.C. 142, para. 164).  While elements of the factual basis 
and/or the sound line of reasoning that form part of the common general knowledge need not be 
disclosed, elements known only to the applicant must be included in the description. 
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This outcome is a departure from pre-Lilly jurisprudence in Canada.
92
  In 
Consolboard Inc. v. MacMillan Bloedel (SASK), the Supreme Court of Canada 
previously had held that the “new and useful” requirement is distinct from the 
requirement of what the specification must disclose in a patent application.
93
  
Specifically, the Supreme Court reasoned that the “new and useful” requirement 
imposes a condition precedent, from which the disclosure requirement is 
independent.
94
  The Supreme Court held, however, that the inventor was not 
obligated, as part of the “new and useful” requirement, to describe in the 
specification why the invention is useful so long as the specification describes the 
invention in sufficient detail such that it can be practiced.
95
  The current sound 
prediction disclosure requirement as incorporated within the MOPOP following 
Lilly, however, obligates applicants to describe a basis of a sound prediction of 
utility “through the specification alone.”
96
 
Thus, according to the doctrine of sound prediction, an examiner or court must 
first construe the promise of the patent of the claimed invention before evaluating 
whether the specification provides a sound line of reasoning linking the construed 
promise of the patent to the factual basis thereof.  If the utility of the claimed 
invention is misconstrued, a proper determination of whether a sound prediction 
exists cannot be made.  Further, because applicants are not required to explicitly 
identify the utility in the specification, the utility of a claimed invention can be 
misconstrued by fact finders such that the sound prediction analysis may not be 
targeted properly to that which the applicant intended.  The result can be 
conflicting conclusions as to the promise of the patent. 
                                                                                                                                     
91
 We have considered whether the proper disclosure prong effectively creates a new written 
description requirement, or whether it merely shifts the statutory basis with respect to an existing 
written description requirement, but found this to be beyond the scope of this article.  In the future 
we would like to explore whether Apotex effectively creates a new written description requirement 
by the third prong of the doctrine of sound prediction, given that the doctrine arises under § 2 of 
the Patent Act rather than § 27(3), which governs all other Canadian written description 
requirements. 
92
 The shift in the doctrine of sound prediction began with the Supreme Court decision Apotex, 
and was expanded with the Federal Court of Appeal’s decision in Lilly.  See supra notes 15–16. 
93
 Consolboard, Inc. v. MacMillan Bloedel (Sask.), Ltd., [1981] 1 S.C.R. 504 (Can.) see also 
Canadian Patent Act § 27(3) (1996). 
94
 Consolboard, Inc., [1981] 1 S.C.R. 504 at 527 (the court distinguished the new and useful 
requirement from the disclosure requirement: “The first is a condition precedent to an invention, 
and the second is a disclosure requirement, independent of the first.”). 
95
 See id. 
96
 Eli Lilly Can. Inc. v. Apotex Inc., [2009] F.C.A. 97 (Can.); MOPOP, supra note 62, § 
12.08.04c. 
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Illustrating the risks associated with this approach, in 2011 the Federal Court 
of Appeal rendered two decisions pertaining to the same patent and reached 
opposite conclusions as to utility.  In Pfizer Canada Inc. v. Canada, the Federal 
Court of Appeal upheld a finding that Canadian Patent No. 1,339,132 (the ‘132 
Patent) was not lacking in utility based on the test results disclosed in the 
specification.
97
  However, in the subsequent case of Apotex Inc. v. Pfizer Canada 
Inc., which dealt with the same ‘132 Patent, the Federal Court of Appeal held that 
the patent was invalid for lacking utility.
98
  In the latter case, the Federal Court of 
Appeal found that the judge had incorrectly construed the utility of the claimed 
invention, and it held that had the judge correctly construed the utility 




Canadian patent law therefore significantly departs from that of the United 
States and Europe via the doctrine of sound prediction, which requires applicants 
to provide, at the time of filing, the factual basis and line of reasoning for a 
prediction of the promise of the patent.  It is also a departure from existing 
international patent agreements to which Canada is a party. 
III. TREATIES AND OTHER INTERNATIONAL AGREEMENTS 
Many of the similarities in the requirements for patentability among the 
United States, Europe, and Canada may be attributed to treaty obligations, and to 
the general trend toward harmonization that has resulted from our increasingly 
interconnected global economy.  A fundamental goal of each of the agreements 
discussed below, whether the agreement is specifically directed to patents and 
intellectual property or is a broader agreement that includes patent and intellectual 
property provisions, is harmonization and the creation of international norms to 
permit the equal treatment of inventions and inventors across borders. The 
doctrine of sound prediction and the heightened utility requirement that it creates 
arguably serve to defeat that goal. 
A. Paris Convention  
The United States, the countries of Europe, and Canada are among the 
contracting states of the Paris Convention for the Protection of Industrial Property 
(Paris Convention).
100
  The Paris Convention is administered by the World 
                                                                                                                                     
97
 See Pfizer Can., Inc. v. Canada, [2011] F.C.J. 406, para. 37 (Can.). 
98
 Apotex Inc. v. Pfizer Can. Inc., [2011] F.C.A. 236, para. 32 (Can.). 
99
 Id. para. 52–53. 
100
 Contracting Parties, WIPO, 
http://www.wipo.int/treaties/en/ShowResults.jsp?lang=en&treaty_id=2 (last visited Feb. 17, 
2012).  The Paris Convention has a total of 174 contracting parties.  Id. 
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Intellectual Property Organization (WIPO), which also administers the Patent 
Cooperation Treaty (PCT) and the Patent Law Treaty (PLT), discussed infra, both 
of which are Special Agreements under Article 19 of the Paris Convention.
101
   
A bedrock principle of the Paris Convention is national treatment, which 
requires each contracting state to grant the same protection to nationals of the 
other contracting states as it grants to its own nationals.
102
  The doctrine of sound 
prediction, however, tends to disadvantage foreign nationals and thus arguably 
impinges on the principle of national treatment.  By insisting that applications 
disclose supporting evidence at a level of proof not required by foreign 
applicants’ own national jurisdictions (and therefore not of the type that foreign 
applicants typically disclose in their priority applications), the doctrine of sound 
prediction renders applications filed by foreign nationals and their ensuing patents 
especially subject to invalidation for lack of utility. 
B. PCT  
The Patent Cooperation Treaty (PCT) entered into force in 1978 and was 
created to provide applicants with a user-friendly, cost-effective, and efficient 
system for filing international patent applications.
103
  Under the PCT, an applicant 
may seek patent protection in some or all of the 144 member countries 
simultaneously by filing a single international application.
104
  Canada, the United 




The PCT and the Regulations under the PCT set forth harmonizing 
requirements for the international application.  Moreover, according to Article 11 
of the treaty, an international application has the same legal effect as a national 
application in each member country in which an applicant chooses to pursue 
                                                                                                                                     
101
 See WIPO-Administered Treaties, WIPO, http://www.wipo.int/treaties/en/index.jsp (last 
visited Feb. 17, 2012).  WIPO administers a total of 24 treaties, including those that prescribe 
norms of intellectual property protection (for example, the PLT), those that establish global 
protection systems (for example, the PCT), and those that create intellectual property classification 
systems.  Id. 
102
 Paris Convention for the Protection of Industrial Property art. 2, Mar. 20, 1883, 21 U.S.T. 
1583 [hereinafter Paris Convention] (as amended Sept. 28, 1979), available at 
http://www.wipo.int/treaties/en/ip/paris/pdf/trtdocs_wo020.pdf. 
103
 See Patent Cooperation Treaty pmbl., June 19, 1970, 28 U.S.T. 7645 [hereinafter PCT], 
available at http://www.wipo.int/pct/en/texts/pdf/pct.pdf. 
104
 See id.  art. 1, 3; WIPO, PCT Applicant’s Guide - International Phase, Annex A 
[hereinafter PCT Applicant’s Guide], http://www.wipo.int/pct/guide/en/gdvol1/pdf/gdvol1.pdf. 
105
 See PCT Applicant’s Guide, supra note 104. 
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  The international application, when undergoing national 
phase examination in a member country, is then subject to the same national laws 
and requirements as a national application filed in that member country.
107
 
Chapter 14 of the PCT International Search and Preliminary Examination 
Guidelines (PCT Guidelines) addresses industrial applicability, which is deemed 
to be synonymous with utility.
108
  The PCT Guidelines consider an invention to be 
industrially applicable if it has specific, substantial, and credible utility.
109
  The 
methodology for assessing industrial applicability under the PCT Guidelines is to: 
(1) determine what the applicant has claimed;
110
 and (2) determine whether a 
person skilled in the art would recognize the claimed invention to have industrial 
applicability.
111
  Identical to the EPO Examination Guidelines, the PCT 
Guidelines provide that “[i]n most cases, industrial applicability will be self-
evident and no more explicit description on this point will be required.”
112
 
Article 27(1) of the PCT addresses the national requirements that member 
countries may impose on international applications: “No national law shall require 
compliance with requirements relating to the form or contents of the international 
application different from or additional to those which are provided for in this 
Treaty and the Regulations.”
113
  In accordance with Article 27(1), member 
countries therefore should not implement form or content requirements that 
exceed or differ from those of the PCT, as such requirements work against the 
international filing concept and violate the terms of the PCT.
114
  The Post-
Conference Documents contained in the Records of the Washington Diplomatic 
Conference on the PCT, which include a chronological account of the main 
                                                                                                                                     
106
 See About the Patent Cooperation Treaty, WIPO, 
http://www.wipo.int/pct/en/treaty/about.html (last visited Feb. 17, 2012); WIPO, PROTECTING 
YOUR INVENTIONS ABROAD: FREQUENTLY ASKED QUESTIONS ABOUT THE PATENT COOPERATION 
TREATY (PCT)  3–4 (Apr. 2006) [hereinafter PROTECTING YOUR INVENTIONS ABROAD], 
http://www.wipo.int/export/sites/www/pct/en/basic_facts/faqs_about_the_pct.pdf (last visited Feb. 
17, 2012).  
107
 See PROTECTING YOUR INVENTIONS ABROAD, supra note 106, at 14–15 
108
 PCT GUIDELINES, supra note 2, § 14.01. 
109
 Id. § A14.01[1].  The PCT Guidelines provide alternative guidelines for utility and 
industrial applicability, such that “[a]n International Authority may rely upon either.”  Id. § 
A14.01.  Both utility and industrial applicability should be familiar from the discussion supra Part 
II.  Much of the language and many of the examples given in the Appendix to Chapter 14 are the 
same as or very similar to that which appears in the MPEP, EPO Examination Guidelines and 
MOPOP; accordingly, the discussion will not be repeated here. 
110




 Id. § 14.05; cf. EPO EXAMINATION GUIDELINES, supra note 3 and accompanying text. 
113
 PCT, supra note 103, art. 27(1). 
114
 See id. 
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decisions and consultations leading to the adoption of the PCT and its 
Regulations,
115
 state that “[f]orm and contents mean not only the physical 




Rule 5.1 of the Regulations under the PCT is directed to the manner of the 
description and provides that the description in an international application 
should:  
[I]ndicate explicitly, when it is not obvious from the description or 
nature of the invention, the way in which the invention is capable 
of exploitation in industry and the way in which it can be made and 
used, or, if it can only be used, the way in which it can be used.
117
   
An international application therefore must demonstrate, either explicitly or 
implicitly, the way in which the invention is capable of being exploited and used, 
i.e., the invention’s utility.  However,  the PCT in Rule 5.1 contemplates 
variations in the manner in which an invention will be described based upon the 
nature of the invention, and it therefore abstains from dictating the particular 
manner in which utility must be substantiated.
118
  The sole exception is expressly 
set forth in Rule 5.2 for nucleotide and/or amino acid sequence disclosures, for 
which the PCT requires a sequence listing.
119
  In all other cases, if a member 
country requires evidence in a particular form in respect of utility, it may only 
oblige the applicant to furnish such evidence during prosecution in the national 
phase. 
Despite Rule 5, the Canadian Court of Appeal has ruled, as for example in the 
Lilly case, that there is an additional requirement that applicants filing Canadian 
patent applications through the PCT must face where the invention is based on a 
sound prediction.
120
  In such cases, applicants must not only disclose the factual 
basis and line of reasoning for their sound prediction, but they must also provide 
the disclosure in the patent specification as filed.
121
  An additional requirement of 
                                                                                                                                     
115
 WIPO, POST-CONFERENCE DOCUMENTS: RECORDS OF THE WASHINGTON DIPLOMATIC 
CONFERENCE, 741, ¶ 1 (1970), available at 
http://www.wipo.int/export/sites/www/pct/en/texts/pdf/washington_p739_to_764.pdf. 
116
 Id. at 751, ¶ 57. 
117
 Regulations Under the PCT, R. 5.1(a)(vi) (July 1, 2011), available at 
http://www.wipo.int/pct/en/texts/rules/r5.htm.  The Rule continues: “[T]he term ‘industry’ is to be 
understood in its broadest sense as in the Paris Convention for the Protection of Industrial 




 Id. at R. 5.2. 
120
 Eli Lilly Can. Inc. v. Apotex Inc., [2009] F.C.A. 97, para. 14 (Can.). 
121
 Id. 
[3:1 2012] Usefulness Varies by Country:             
23 
The Utility Requirement of Patent Law  




this sort concerning the contents of an application is contrary to, and indeed 
defeats the purpose of, the PCT.
122
 
C. PLT  
The Patent Law Treaty (PLT),
123
 the scope of which covers both national and 
regional applications, is also directed toward procedural standards of patent 
protection to be provided by member states.
124
  The PLT aims “to harmonize and 
streamline formal procedures in respect of national and regional patent 
applications and patents.”
125
   
The United States and Canada each signed the PLT but have not yet ratified it.  
Among the European Patent Organisation member countries, the following are 
PLT member states: Albania, Denmark, Estonia, Finland, France, Hungary, 
Latvia, Lithuania, Macedonia, Montenegro,
126
 the Netherlands, Romania, Serbia, 
Slovakia, Slovenia, Sweden, Switzerland, and the United Kingdom.
127
 
Article 6(1) of the PLT extends the form and contents requirements of the 
PCT to all patent applications, not just international ones, by prohibiting member 
countries from demanding compliance with any requirement relating to form and 
contents other than those provided for in the PCT.
128
 Moreover, Article 6(6) of the 
                                                                                                                                     
122
 See supra note 113.  Surprisingly, in reaching its decision in the Lilly case, the Court of 
Appeal relied upon PCT Article 27(5), which provides in part that “[n]othing in this Treaty and the 
Regulations is intended to be construed as prescribing anything that would limit the freedom of 
each Contracting State to prescribe such substantive conditions of patentability as it desires.” 
Substantive conditions of patentability, however, do not include the contents of the application, 
but rather relate to novelty, inventive step, and utility. Moreover, the article expressly provides 
that the freedom to prescribe does not extend to conditions of patentability “constituting 
requirements as to the form and contents of applications.”  PCT, supra note 103, art. 27(5); Lilly, 
[2009] F.C.A. 97, para. 19. 
123
 Treaties, Laws, and Practices: Patent-Related Treaties Administered by WIPO,  WIPO, 
http://www.wipo.int/patent-law/en/treaties.html (last visited Feb. 16, 2012). 
124
 Summary of the Patent Law Treaty (2000), WIPO,  




 Montenegro is an EPO extension state.  Extension States, EUROPEAN PAT. OFF., 
http://www.epo.org/about-us/organisation/member-states/extension-states.html (last visited Feb. 
16, 2012). 
127
 Compare Member States of the European Patent Organisation, EUROPEAN PAT. OFF., 
http://www.epo.org/about-us/organisation/member-states.html (last visited Feb. 16, 2012), with 
Contracting Parties: Patent Law Treaty, WIPO, 
http://www.wipo.int/treaties/en/ShowResults.jsp?lang=en&treaty_id=4 (last visited Feb. 16, 
2012).     
128
 Patent Law Treaty art. 6(1), June 1, 2000, U.N.T.S. Reg. No. I-41939 (“[Form or Contents 
of Application] Except where otherwise provided for by this Treaty, no Contracting Party shall 
require compliance with any requirement relating to the form or contents of an application 
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treaty limits a patent office’s authority to require applicants to file evidence “in 
the course of the processing of the application only where that Office may 
reasonably doubt the veracity of that matter.”
129
 The regulations under the PLT 
require the patent office to state its reason for doubting that veracity.
130
 
D. TRIPS and NAFTA 
The Agreement on Trade-Related Aspects of Intellectual Property Rights 
(TRIPS) is another treaty to which the United States, European countries, and 
Canada are obligated.
131
  Canada and the United States are also signatories to the 
North American Free Trade Agreement (NAFTA),
132
 which, like TRIPS, provides 
that "patents shall be available for any inventions, whether products or processes, 
in all fields of technology, provided they are new, involve an inventive step and 
are capable of industrial application.”
133
  TRIPS “establishes minimum levels of 
protection that each government has to give to the intellectual property of fellow 
[World Trade Organization] members.”
134
  Non-discrimination is a core goal, not 
only as between nationals and foreigners, but also as to the technological field of 
an invention, the place of its creation, and whether it was imported or locally 
produced.
135
  TRIPS has another important principle: “[I]ntellectual property 
protection should contribute to technical innovation and the transfer of 
                                                                                                                                     
 
different from or additional to:  (i) the requirements relating to form or contents which are 
provided for in respect of international applications under the Patent Cooperation Treaty . . . .”). 
129
 Id. art. 6(6). 
130
 Regulations Under the Patent Law Treaty, R. 5, WIPO (Jan. 1, 2006), 
http://www.wipo.int/treaties/en/ip/plt/trtdocs_wo039.html. 
131
 See Members and Observers, Understanding the WTO: The Organization, WORLD TRADE 
ORG., http://www.wto.org/english/thewto_e/whatis_e/tif_e/org6_e.htm (last visited Feb. 16, 
2012). 
132
 North American Free Trade Agreement, U.S.-Can.-Mex., Dec. 17, 1992, 32 I.L.M. 289 
(1993) [hereinafter NAFTA], available at http://www.ustr.gov/trade-agreements/free-trade-
agreements/north-american-free-trade-agreement-nafta.  Mexico is the third NAFTA signatory.  
Id. 
133
 Agreement on Trade-Related Aspects of Intellectual Property Rights art. 27.1, April 15, 
1994, 1869 U.N.T.S. 299 [hereinafter TRIPs], available at 
http://www.wto.org/english/res_e/booksp_e/analytic_index_e/trips_02_e.htm#article27; NAFTA 
art. 1709.1.  “Capable of industrial application” and “useful” are synonymous in the agreements.  
Compare TRIPS, supra, with NAFTA, supra  note 132. 
134
 Understanding the WTO: The Agreements, Intellectual Property: Protection and 
Enforcement,  WORLD TRADE ORG., 
http://www.wto.org/english/thewto_e/whatis_e/tif_e/agrm7_e.htm (last visited Feb. 16, 2012). 
135
 See Overview: The TRIPS Agreement, WORLD TRADE ORG., 
http://www.wto.org/english/tratop_e/trips_e/intel2_e.htm (last visited Feb. 16, 2012). 
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technology.  Both producers and users should benefit, and economic and social 
welfare should be enhanced.”
136
   
In an effort to strike a balance between the objective of providing incentives 
for pharmaceutical invention and the demands of providing access to public 
health, the TRIPS Agreement has paid special attention to the patenting of 
pharmaceutical products.  For example, the TRIPS Agreement permits member 
countries to benefit from important flexibilities, including the adoption of 
compulsory licensing provisions to help ensure the adequate supply of 
pharmaceuticals, but it stops short of permitting differential treatment in the 
examination of pharmaceutical patent applications.
137
 
A country that has ratified the Paris Convention, the PCT and/or the PLT has 
agreed to treat all patent applications filed in that country uniformly, regardless of 
whether the applications are filed under one of those conventions or the national 
laws of the country.  Imposing national form and contents requirements beyond 
those of the harmonizing international treaties undermines a fundamental purpose 
of the agreements: uniform treatment of domestic and foreign-origin applications, 
irrespective of the convention under which the foreign-origin application is filed.  
A country that has ratified the TRIPS Agreement, moreover, has agreed not to 
single out applications in particular areas of technology for discriminatory 
treatment.  The body of treaties and agreements thus forms part of an international 
patent law framework within which patent applicants operate.  This framework is 




IV. AN INTERJURISDICTIONAL CASE STUDY 
Given the frequency with which owners of technology seek protection for 
their inventions in multiple countries,
139
 it is not infrequent for patent or patent 
application members of a single patent family to be the object of similar litigation 
in several jurisdictions simultaneously.  The following case study involves 
judicial (courts in Canada and the United States) and administrative (EPO 
Technical Board of Appeal in Europe) treatment of a patent family owned by the 
                                                                                                                                     
136
 Understanding the WTO: The Agreements, Intellectual Property: Protection and 
Enforcement, supra note 134 (emphasis added).  “The [TRIPS] Agreement covers five broad 
issues: how basic principles of the trading system and other international intellectual property 
agreements should be applied; how to give adequate protection to intellectual property rights[;] 
how countries should enforce those rights adequately in their own territories[;] how to settle 
disputes on intellectual property between members of the WTO[; and] special transitional 




 See supra note 9 and accompanying text. 
139
 See supra note 9 and accompanying text. 
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pharmaceutical company AstraZeneca.  The patent family originated with a 
Swedish patent application
140
 filed on May 28, 1993 that was generally directed to 
optically pure salts of omeprazole,
141
 which have a superior therapeutic profile to 
omeprazole salts having mixed enantiomers.
142
  On May 27, 1994, the applicant 
filed European and PCT applications claiming priority to the Swedish parent 
application.
143
  The applicant subsequently filed Canadian, United States, and 
other national phase applications based on the PCT application, with priority 
being claimed back to the Swedish application.
144
 
The Canadian patent, No. 2,139,653 (‘653 patent), was challenged in 2010 in 
AstraZeneca Canada Inc. v. Apotex Inc., in which Apotex alleged that the ‘653 
patent was invalid for lack of utility.
145
  The patent describes omeprazole as a 
gastric acid secretion inhibitor “useful as [an] antiulcer agent[s],” but can have 
two possible enantiomers.
146
 As such, the patent describes and claims the present 
invention as a series of omeprazole salts having a single enantiomer 
(esomeprazole) and a process for making single enantiomer compounds having 
improved pharmacokinetic and metabolic properties.
147
  Instead of looking to the 
stated utility of the claimed compounds, the court reasoned that the utility of the 
claimed invention was an “improved therapeutic profile” made possible by the 
single enantiomer salts.
148
  In response to this court-constructed utility, 
AstraZeneca presented evidence that prior to the priority date of the Canadian 
patent, AstraZenca researchers had found that pure salts of enantiomers, including 
esomeprazole, could provide improved therapeutic results.  The court nevertheless 
rejected the evidence because the report detailing the information was not 
                                                                                                                                     
140
 S.E. Application No. 19931830A (filed May 28, 1993); PCT Application No. 
PCT/SE94/00830 (filed May 27, 1994). 
141
 Omeprazole is a chemical compound that acts as a proton pump inhibitor for treating gastric 
disorders. Omeprazole, DRUGBANK, http://www.drugbank.ca/drugs/DB00338#pharmacology (last 
updated Feb. 14, 2012). 
142
 Enantiomers are different configurations of substituents on a tetrahedral carbon or other 
atom.  GEORGE ODIAN, PRINCIPLES OF POLYMERIZATION 621 (4th ed. 2004). 
143
 E.P. Application No. 1 020 460A (filed May 27, 1994) (now issued as E.P. Patent No. 1 020 
460B); PCT Application No. PCT/SE94/00830 (filed May 27, 1994). 
144
 C.A. Application No. 2139653A (filed December 08, 1994) (now issued as C.A. Patent No. 
2139653B); U.S. Patent Application No. 08/376,512 (filed January 23, 1995) (now issued as U.S. 
Patent 5,714,504). 
145
 AstraZeneca Can. Inc. v. Apotex Inc., [2010] F.C. 714 (Can.).  
146




 AstraZeneca Can. Inc., [2010] F.C. 714, para. 82–84.  The court’s reasoning seems to 
deviate from that of other countries since the nature of “improved” is not a concern for utility but 
rather for obviousness.  Under Canadian law, patents are awarded for inventions which are not 
devoid of utility, and the measure of an invention’s improvement over the art should be a separate 
concern. 
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presented until after the filing date of the Canadian application and was not 
mentioned in the specification.
149
  Consequently, the Court invalidated the claims 
at issue as lacking a sound prediction, because the applicant failed to show that as 
of the priority date the inventors had a factual basis for a prediction that an 
esomeprazole salt of a particular purity would have the utility indicated in the 
patent.  
In contrast, in Astrazeneca AB v. Hanmi USA, Inc., Hanmi alleged that U.S. 
Patent 5,714,504 (‘504 patent), an equivalent application to the Canadian ‘653 
patent, was invalid for lack of enablement, written description, and other theories, 
but it did not even assert that the patent was invalid for lack of utility, although 
the Canadian ‘653 patent had already been invalidated on that ground.
150
  
Although the defendant argued that the specification of the ‘504 patent was 
lacking in virtually every way, the defendant did not raise lack of utility, no doubt 
because the stated utility of the compounds as gastric acid secretion inhibitors, 
which was expressly taught in the patent specification, would be considered 
sufficient to meet the utility requirement under the U.S. law.
151
  
The European counterpart to the Canadian ‘653 patent and the United States 
‘504 patent was European Patent No. 0652872 (‘872 patent).  Its fate was 
addressed in an EPO opposition proceeding.
152
  The decision of the EPO 
Technical Board of Appeal in that case was to revoke certain claims of the ‘872 
patent, and in reaching its decision, the Board relied upon the “use” constructed 
by the Canadian Court to invalidate the ‘653 Patent.
153
  As with the Canadian 
court, the Board based its decision to revoke the patent on the “improved 
therapeutic profile.” However, unlike the Canadian counterpart case, the Board 
did not invalidate the patent for lack of utility, but instead held that the “improved 
therapeutic profile” from single enantiomer salts was obvious to a person of skill 
in the art.
154
  As in the United States counterpart case, the Board accepted the 
proposed use, and even relied upon the proposed use, without questioning its 
validity. 
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 Id. para. 86–90. 
150
 AstraZeneca AB v. Hanmi USA, Inc., No.11–760(JAP), 2011 WL 5526009, at *6 (D.N.J. 
Nov. 14, 2011). 
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 Though this litigation remains pending, utility remains unchallenged.  Id. 
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V. PRACTICAL IMPLICATIONS OF CANADA’S DOCTRINE OF SOUND PREDICTION 
The doctrine of sound prediction effectively imposes a heightened utility 
requirement on patent applicants in Canada and has broad implications, both 
nationally and internationally.  First, the heightened utility requirement may 
create a new, potentially unintended class of unpatentable subject matter unique to 
Canada if selectively used to target a particular type of invention.  Second, it 
exceeds existing international utility standards, raising questions with respect to 
Canada’s obligations under international treaties and potentially leading to 
disparate treatment of domestic and foreign-origin applications within Canada.  
Finally, it could present a significant hurdle to increased global patent law 
harmonization going forward. 
With respect to policy, others have noted that utility challenges to Canadian 
patent applications have been almost exclusively directed at pharmaceutical 
patents.
155
  Therefore, the doctrine of sound prediction, or at least its focused 
application, may be an attempt to implement a policy change in Canada with 
respect to certain classes of inventions, namely pharmaceutical.  Canada has been 
accused in the past of “treating patent holders in the field of pharmaceutical 
inventions . . . less favorably than inventions in all other fields of technology,” 
which resulted in a complaint being filed against Canada under the WTO TRIPS 
Dispute Resolution procedures.
156
  The patent system, however, should not be 
manipulated to implement such a policy change.  Rather, policy issues should be 
addressed transparently if it is desired, on some level, to promote a new course. 
Turning to the international agreements, as a signatory to the Paris 
Convention, PLT, PCT, TRIPS, and NAFTA, Canada has agreed to treat all 
patent applications filed in its patent office uniformly, regardless of whether the 
applications are filed under one of the international conventions (e.g., the Paris 
Convention, PLT and PCT) or the national law of Canada.
157
  Imposing national 
form and content requirements beyond those of the harmonizing international 
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 See supra note 12 and accompanying text. 
156
 Panel Report, Canada – Patent Protection of Pharmaceutical Products, WT/DS114/R (Mar. 
17, 2000).  This treatment was alleged to violate Canada’s obligations under Article 27.1 of 
TRIPS.  Id.; see generally supra Part III.D.  Canada was also accused of violating Articles 28.1 
and 33 of TRIPS.  Id.  Ultimately, Canada was found to be in compliance with Articles 27.1 and 
28.1 (with respect to § 55.2(1) of the Canadian Patent Act) but in violation of Article 28.1 (with 
respect to § 52.2(2) of the Canadian Patent Act).  Id. at 174.  Article 28.1 of TRIPS addresses 
rights conferred on patent owners.  TRIPS, supra note 133, art. 28.1.  Following the Report of the 
Panel, Canada announced it would implement the Panel’s findings, and in October 2000 revoked 
the necessary regulations.  KRISTEN DOUGLAS & CELIA JUTRAS, CANADIAN PARLIAMENTARY 
INFO. AND RESEARCH SERV., PRB 99-46E, PATENT PROTECTION FOR PHARMACEUTICAL PRODUCTS 
IN CANADA – CHRONOLOGY OF SIGNIFICANT EVENTS, (Rev’d Oct. 6,  2008). 
157
 See supra Part III. 
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treaties, which is an effect of Canada’s doctrine of sound prediction, undermines 
uniform treatment of domestic and foreign-origin applications, irrespective of the 
convention under which the foreign-origin application is filed.   
Furthermore, the doctrine of sound prediction creates potential traps that can 
ensnare foreign
158
 applicants.  As discussed supra, United States patent law is 
similar to that of Canada and requires that an invention must be useful in order to 
be patentable.
159
  Specifically, a specific, substantial, and credible use for the 
invention must be disclosed in the specification of a United States patent 
application.
160
  Unlike the Canadian doctrine of sound prediction, under United 
States law, the applicant is not required to provide evidence that the connection 
between the proposed use and the claimed invention is well-reasoned.
161
 While 
Europe uses the phrase “industrial applicability,” it is analogous to the utility 
requirements of United States and Canadian law, as discussed supra.
162
  An 
invention has industrial applicability if the invention “can be made or used in any 
kind of industry.”
163
  Like in United States law, Europe simply requires that the 
industrial applicability of the invention be identified and does not require a 
showing that the identified industrial applicability be selected as a result of sound 
prediction based on the disclosure in the patent.
164
  As a result, Canadian patent 
applications and patents arising from foreign applications or patents, including 
United States and European applications or patents, are particularly vulnerable to 
invalidation for lacking utility, because United States and European law only 
require that the utility be specified, while Canadian law invokes the heightened 
evidentiary standard.
165
  Because other jurisdictions do not require the same 
evidentiary standard, foreign-origin specifications likely will not include the 
supporting evidence required by Canada alone.  Therefore, Canadian patents 
based on foreign applications drafted under conventional international utility 
requirements, including those of the PCT to which Canada is a signatory party, 
are vulnerable to the shifting evidentiary requirements associated with complying 
with the doctrine of sound prediction.  In imposing on patent applicants 
heightened standards that go beyond the letter and intent of the various 
international agreements to which Canada is party, Canada has ignored its 
international obligations.    
                                                                                                                                     
158
 “Foreign” is used here with respect to Canada (i.e., non-Canadian). 
159
 U.S. CONST. art. 1, § 8, cl. 8. 
160
 35 U.S.C. §§ 101, 112 (2006); see also MPEP, supra note 5, § 2164.07. 
161
 See id. 
162




 See supra Part II. 
165
 See supra Part II. 
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Finally, Canada’s heightened utility requirements present a barrier to 
increased global patent law harmonization.  Increased harmonization will be 
difficult if nations do not abide by current obligations, never mind anticipated and 
future ones intended to harmonize national laws.  Given the increasingly global 
economy in which innovators operate, jurisdictions that are unwilling or unable to 
commit to broadly supported harmonization goals may be left behind, presenting 
ever higher hurdles to their innovators and economies.  
